secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2024-11-20T23:59:59+00:00
Accession:  0000950170-24-129018
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo reports first RAINIER trial patient achieved 90% leukemic blast reduction in 30 days
--------------------------------------------------------------------------------

- First patient in Phase 1b/2 RAINIER trial achieved 90% reduction in leukemic blasts within first 30 days.
- Mipletamig (CD3 x CD123 bispecific) evaluated as frontline therapy in combination with venetoclax and azacitidine for AML.
- Data builds on prior studies showing strong safety profile with manageable CRS below comparable treatment modalities.
- RAINIER is designed for statistically defined efficacy analysis in newly diagnosed patients with limited options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000095017024129018/0000950170-24-129018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000095017024129018/apvo-20241120.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-129018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer